AddexBio

AddexBio is a hybrid-stage biotech company that combines an internal oncology drug discovery pipeline with an extensive portfolio of preclinical contract research services (CRO). Its core focus is on developing small molecules that disrupt cancer metabolism, a promising therapeutic approach. The company leverages its service arm to generate revenue and potentially de-risk its own R&D efforts. AddexBio appears to be a private, preclinical-stage company operating in the competitive but high-potential oncology space.

Integrated small molecule drug discovery platform focused on cancer metabolism, supported by extensive in-house capabilities in medicinal chemistry, bioanalytical screening, ADME, DMPK, in vivo pharmacology, and a vast repository of cell lines and assay reagents.

In drug development, AddexBio competes with numerous biotechs and pharma companies pursuing cancer metabolism targets. In CRO services, it faces competition from large global CROs (e.g., Charles River, Labcorp) and specialized niche providers. Its differentiation lies in combining deep oncology/biology expertise with chemistry services.